☆ 4.6 Article

Implementation of Pharmacogenetics in First-Line Care: Evaluation of Its Use by General Practitioners

GENES (2023)

Related references

Note: Only part of the references are listed.

Review Biochemistry & Molecular Biology

Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan

Emma C. Hulshof et al.

Summary: The Dutch Pharmacogenetics Working Group has developed evidence-based guidelines for the optimal starting dose of the anti-cancer drug irinotecan, based on UGT1A1 gene variants. UGT1A1 genotyping is considered essential prior to initiating irinotecan treatment to decrease the risk of severe toxicity.

EUROPEAN JOURNAL OF HUMAN GENETICS (2023)

Add to Collection

Article Medicine, General & Internal

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

Jesse J Swen et al.

LANCET (2023)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants

Chad A. Bousman et al.

Summary: Selective serotonin reuptake inhibitors (SSRIs) are the primary pharmacologic treatments for major depressive and anxiety disorders. Genetic variation in CYP2D6, CYP2C19, and CYP2B6 can affect the metabolism of these antidepressants, potentially impacting dosing, efficacy, and tolerability. The SLC6A4 and HTR2A genes have been studied for their relationship with efficacy and side effect profiles of these drugs. This guideline updates and expands on the role of genetic factors in antidepressant response and provides recommendations for using genotype results to guide prescribing decisions.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

Add to Collection

Article Pharmacology & Pharmacy

Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype

Roseann S. Gammal et al.

Summary: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is associated with the development of acute hemolytic anemia in the presence of oxidative stress. This guideline provides information on using G6PD genotype for diagnosing G6PD deficiency and categorizes medications based on their risk level in individuals with G6PD deficiency. High-risk medications should be avoided, medium-risk medications should be used with caution, and low-risk medications can be used without considering the G6PD phenotype.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics

Lianne Beunk et al.

Summary: The Dutch Pharmacogenetics Working Group (DPWG) has developed evidence-based guidelines to optimize pharmacotherapy by promoting the implementation of pharmacogenetics in clinical practice. This guideline describes the gene-drug interactions between CYP2D6, CYP3A4, CYP1A2 genes and antipsychotics. The DPWG recommends therapy adjustments based on genotype for certain antipsychotics, such as dose reduction for CYP2D6-predicted poor metabolizers (PMs) and dose increase or alternative drug for ultra-rapid metabolizers (UMs). Limited evidence suggests alternative drug choice or dose reduction for quetiapine and CYP3A4 PMs. No therapy adjustments are recommended for other predicted phenotypes.

EUROPEAN JOURNAL OF HUMAN GENETICS (2023)

Add to Collection

Article Pharmacology & Pharmacy

Healthcare professionals' knowledge, confidence and perceptions of pharmacogenomics in primary care and pain management

Matthew P. Behr et al.

Summary: This study aimed to assess the knowledge, confidence, and perceptions of healthcare professionals at Brigham and Women's Hospital specializing in primary care and pain management regarding clinical pharmacogenomics (PGx). A 25-question online survey was distributed to 328 clinicians, and the results showed that respondents had limited experience and awareness of PGx resources. While believing in the utility of PGx to improve patient outcomes, many lacked confidence in applying PGx results to their practice. This study highlights the need for more clinician education on the appropriate utilization of PGx in primary care and pain management.

PHARMACOGENOMICS (2023)

Add to Collection

Article Pharmacology & Pharmacy

Attitudes about pharmacogenomic testing vary by healthcare specialty

Charlene L. Preys et al.

Summary: The aim of the study was to understand the variation in attitudes towards pharmacogenomic (PGx) testing among healthcare providers by specialty. The results showed that primary care providers were more likely to rate PGx testing as useful compared to specialty care providers. Education increased comfort ordering PGx tests, with a greater impact on primary care providers. Over 90% of cardiology and internal medicine providers rated PGx testing as useful both before and after education.

PHARMACOGENOMICS (2023)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update

Craig R. Lee et al.

Summary: CYP2C19 enzyme plays a role in the activation of clopidogrel, and the genotype of CYP2C19 affects the formation of active metabolites of clopidogrel. Thus, using CYP2C19 genotype to guide the use of clopidogrel can reduce the risk of reduced platelet inhibition and major adverse cardiovascular and cerebrovascular events, particularly for intermediate metabolizers.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

Add to Collection

Article Pharmacology & Pharmacy

The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms

Rhonda M. Cooper-DeHoff et al.

Summary: Statins are commonly prescribed medications that reduce cholesterol and prevent cardiovascular disease. However, statin-associated musculoskeletal symptoms can affect patient adherence and long-term effectiveness. Genetic variations in SLCO1B1, ABCG2, and CYP2C9 genes have been identified to impact the metabolism and adverse events of statins. This study summarizes the literature supporting these associations and provides therapeutic recommendations based on genotypes to improve the safety, adherence, and effectiveness of statin therapy.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs

Jurriaan M. J. L. Brouwer et al.

Summary: The study provides detailed analysis on the gene-drug interaction between the genes CYP2C19 and CYP2D6 and selective serotonin reuptake inhibitor (SSRIs) antidepressants, offering specific dosage adjustment recommendations for patients with different genotypes. The results suggest that genotyping before starting specific antidepressants can be beneficial for toxicity/effectivity predictions.

EUROPEAN JOURNAL OF HUMAN GENETICS (2022)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium Guideline for the Use of Aminoglycosides Based on MT-RNR1 Genotype

John Henry McDermott et al.

Summary: The use of aminoglycosides is associated with the risk of hearing loss, particularly in individuals with MT-RNR1 gene variants. It is advisable to avoid using aminoglycosides in individuals with MT-RNR1 variants associated with an increased risk of aminoglycoside-induced hearing loss.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone)

Maja Matic et al.

Summary: The guideline describes the gene-drug interaction between CYP2D6 and the opioids codeine, tramadol and oxycodone, categorizing individuals into different metabolizer types based on genotype. Specific recommendations are provided for each metabolizer type when using these drugs to ensure safe and effective treatment.

EUROPEAN JOURNAL OF HUMAN GENETICS (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction of CYP2D6 and COMT with atomoxetine and methylphenidate

Marga Nijenhuis et al.

Summary: Pharmacogenetics studies the effect of genetic variation on drug response. The Dutch Pharmacogenetics Working Group (DPWG) has developed evidence-based guidelines for optimizing pharmacotherapy based on genetic testing results. This guideline specifically focuses on optimizing atomoxetine therapy based on genetic variation in the CYP2D6 gene.

EUROPEAN JOURNAL OF HUMAN GENETICS (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Dutch pharmacogenetics working group guideline for the gene-drug interaction of ABCG2, HLA-B and Allopurinol, and MTHFR, folic acid and methotrexate

Karel H. van der Pol et al.

Summary: The Dutch Pharmacogenetics Working Group has developed evidence-based guidelines for the implementation of pharmacogenomics, providing guidance on the gene-drug interactions of ABCG2, HLA-B, and MTHFR with specific drugs used in the treatment of gout, cancer, and rheumatoid arthritis. The guidelines recommend adjusting drug dosage or considering alternative drugs based on the patient's genetic profile, with the aim of optimizing therapeutic outcomes and minimizing adverse events.

EUROPEAN JOURNAL OF HUMAN GENETICS (2022)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline forCYP2C19and Proton Pump Inhibitor Dosing

John J. Lima et al.

Summary: Using CYP2C19 genotype data to guide PPI therapy can help identify patients who may need higher doses for efficacy and those who may benefit from lower doses to reduce the risk of toxicity associated with long-term use at higher plasma concentrations.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)

Add to Collection

Review Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline forCYP2C9andHLA-BGenotypes and Phenytoin Dosing: 2020 Update

Jason H. Karnes et al.

Summary: Phenytoin, an antiepileptic drug, is influenced by genetic variations in patients, with individuals carrying the variant allele HLA-B*15:02 having an increased risk of severe skin reactions when receiving phenytoin treatment.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)

Add to Collection

Article Pharmacology & Pharmacy

Estimating the potential impact of implementing pre-emptive pharmacogenetic testing in primary care across the UK

Essra Youssef et al.

Summary: This study aims to quantitatively estimate the impact of a population-level pharmacogenetic screening programme on primary care prescribing in the UK. Results show that actionable drug-gene interactions are common in primary care, suggesting significant opportunities for optimizing prescribing practices.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy

Kristine R. Crews et al.

Summary: Opioids are commonly used for the treatment of acute and chronic pain, and the clinical effects and adverse events are associated with genes such as CYP2D6, OPRM1, and COMT. While there is extensive research on the association between CYP2D6 and codeine/tramadol, data for hydrocodone, oxycodone, methadone, OPRM1, and COMT are more limited.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines

Carin A. T. C. Lunenburg et al.

EUROPEAN JOURNAL OF HUMAN GENETICS (2020)

Add to Collection

Article Pharmacology & Pharmacy

Evaluation of Current Regulation and Guidelines of Pharmacogenomic Drug Labels: Opportunities for Improvements

Rawan Shekhani et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs

Katherine N. Theken et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)

Add to Collection

Article Genetics & Heredity

Implementation of Pharmacogenetics in Primary Care: A Multi-Stakeholder Perspective

Tessel Rigter et al.

FRONTIERS IN GENETICS (2020)

Add to Collection

Review Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy

Jacob T. Brown et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy

Zeruesenay Desta et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)

Add to Collection

Article Genetics & Heredity

Pharmacist-Initiated Pre-Emptive Pharmacogenetic Panel Testing with Clinical Decision Support in Primary Care: Record of PGx Results and Real-World Impact

Cathelijne H. van der Wouden et al.

GENES (2019)

Add to Collection

Article Medicine, General & Internal

Estimated nationwide impact of implementing a preemptive pharmacogenetic panel approach to guide drug prescribing in primary care in The Netherlands

P. C. D. Bank et al.

BMC MEDICINE (2019)

Add to Collection

Article Biochemistry & Molecular Biology

A pilot study of the implementation of pharmacogenomic pharmacist initiated pre-emptive testing in primary care

Paul C. D. Bank et al.

EUROPEAN JOURNAL OF HUMAN GENETICS (2019)

Add to Collection

Review Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update

Mary Relling et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes

Stephen G. Gonsalves et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy

Matthew P. Goetz et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)

Add to Collection

Review Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update

Elizabeth J. Phillips et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

Ursula Amstutz et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update

J. A. Johnson et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron

G. C. Bell et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy

B. Moriyama et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update

J. K. Hicks et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing

R. S. Gammal et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update

Y. Saito et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing

K. A. Birdwell et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors

J. K. Hicks et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon-α-Based Regimens

A. J. Muir et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)

Add to Collection

Article Pharmacology & Pharmacy

The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update

L. B. Ramsey et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Rasburicase Therapy in the Context of G6PD Deficiency Genotype

M. V. Relling et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 Update

M. A. Martin et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update

K. R. Crews et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing

K. E. Caudle et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype

J. P. Clancy et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing

M. S. Hershfield et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing

K. E. Caudle et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update

M. V. Relling et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants

J. K. Hicks et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Carbamazepine Dosing

S. G. Leckband et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update

S. A. Scott et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype

K. R. Crews et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)

Add to Collection

Article Pharmacology & Pharmacy

The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy

R. A. Wilke et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing

M. A. Martin et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing

M. V. Relling et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing

J. A. Johnson et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)

Add to Collection

Article Pharmacology & Pharmacy

Pharmacogenetics: From Bench to Byte-An Update of Guidelines

J. J. Swen et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy

S. A. Scott et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)

Add to Collection

Article Pharmacology & Pharmacy

Pharmacogenetics: From bench to byte

J. J. Swen et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)

Add to Collection

Article Medicine, General & Internal

Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients

M Pirmohamed et al.

BMJ-BRITISH MEDICAL JOURNAL (2004)

Add to Collection

Article Pharmacology & Pharmacy

Adverse drug reactions as a cause of admission to an acute medical assessment unit: a pilot study

CF Green et al.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.